Blood Res.  2017 Mar;52(1):3-6. 10.5045/br.2017.52.1.3.

The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective

• Suh C
• Park BB
• Kim WS
• CISL

• KMID: 2375194
• DOI: http://doi.org/10.5045/br.2017.52.1.3

Abstract

No abstract available.

MeSH Terms

Lymphoma*

Figure

• 

  Fig. 1 Chronological flow of prospective Consortium for Improving Survival of Lymphoma studies. Abbreviations: DLBCL, diffuse large B-cell lymphoma; MZL, marginal zone lymphoma; MCL, mantle cell lymphoma; ENKTL, extranodal NK/T cell lymphoma; HL, Hodgkin lymphoma; ASCT, autologous stem cell transplantation. CISL 0601, concurrent chemo-radiotherapy (CCRT) and weekly cisplatin followed by VIPD (etoposide, ifosfamide, cisplatin and dexamethasone); CISL 0602, radioimmunotherapy with 131I-rituximab; CISL 0603, bortezomib plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) every 2 weeks; CISL 0604, alemtuzumab plus and DHAP (dexamethasone, high-dose cytarabine and cisplatin); CISL 0605, rituximab (R) plus CVP (cyclophosphamide, vincristine and prednisolone); CISL 0606, gemcitabine single agent; CISL 0607, yttrium-90 ibritumomab tiuxetan consolidation following rituximab plus CHOP; CISL 0701, bortezomib plus CHOP; CISL 0702, GIDOX (gemcitabine, ifosfamide, dexamethasone and oxaliplatin); CISL 0801, CCRT followed by VIDL (etoposide, ifosfamide, dexamethasone and L-asparaginase) with risk-based application of ASCT; CISL 0802, ESHAOX (etoposide, methylprednisolone, high-dose cytarabine and oxaliplatin); CISL 0803, intensified 1st cycle R plus 8 cycles of R-CHOP, CISL 0806 and 0901, busulfan, melphalan and etoposide as conditioning; CISL 0905, Ox-P (oxaliplatin and prednisolone); CISL 1001, high-dose methotrexate induction followed by alternative high-dose methotrexate and high-dose cytarabine combination consolidation; CISL 1003, GDP (gemcitabine, dexamethasone and cisplatin); CISL 1004, R augmentation following R-CHOP induction; CISL 1006 and 1107, prospective cohort study with risk-adapted CNS and bone marrow evaluation; CISL 1008, CCRT followed by MIDLE (methotrexate, ifosfamide, dexamethasone, L-asparaginase and etoposide); CISL 1009, R-CVP followed by R maintenance; CISL 1010, R-CVP; CISL 1011, ESHAOX (etoposide, methylprednisolone, high-dose cytarabine and oxaliplatin); CISL 1106, R-CHOP and prophylactic intrathecal methotrexate; CISL 1108, everolimus plus CHOP; CISL 1201, vorinostat plus fludarabine, mitoxantrone and dexamethasone; CISL 1205, comparison intravenous busulfan, melphalan and etoposide versus intravenous busulfan, cyclophosphamide and etoposide as conditioning regimen; CISL 1206, R plus reduced dose CHOP for elderly; CISL 1305, phase II: bortezomib for maintenance in high-risk DLBCL; CISL 1306, pilot study: ruxolitinib in relapsed or refractory HL and primary mediastinal large B-cell lymphoma of high risk; CISL 1402, phase II, erythropoietin for anemia caused by chemotherapy in DLBCL; CISL 1403, prospective cohort registry of DLBCL; CISL 1404, prospective cohort study of peripheral T-cell lymphoma; CISL 1502, phase II, bendamustine, carboplatin and dexamethasone for refractory or relapsed peripheral T-cell lymphoma.

Reference

1. Suh C, Kim WS, Kim JS, Park BB. Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party. Blood Res. 2013; 48:171–177.

2. Kim S, Kim H, Kang H, et al. Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement. J Hematol Oncol. 2013; 6:76.

3. Hyun SY, Cheong JW, Kim SJ, et al. High-dose etoposide plus granulocyte colony-stimulating factor as an effective chemomobilization regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma previously treated with CHOP-based chemotherapy: a study from the Consortium for Improving Survival of Lymphoma. Biol Blood Marrow Transplant. 2014; 20:73–79.

4. Lee SJ, Suh CW, Lee SI, et al. Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study. Korean J Intern Med. 2014; 29:352–360.

5. Kang BW, Sohn SK, Moo JH, et al. Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. Blood Res. 2014; 49:15–21.

6. Lee S, Kim MJ, Kim JS, et al. Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. Blood Res. 2015; 50:242–247.

7. Jeong SH, Moon JH, Kim JS, et al. Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation. Ann Hematol. 2015; 94:617–625.

8. Hong J, Kim SJ, Ahn JS, et al. Treatment outcomes of rituximab plus hyper-CVAD in Korean patients with sporadic Burkitt or Burkitt-like lymphoma: Results of a multicenter analysis. Cancer Res Treat. 2015; 47:173–181.

9. Lee GW, Go SI, Kim SH, et al. Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. Leuk Lymphoma. 2015; 56:1020–1026.

10. Koh MS, Kim WS, Kim SJ, et al. Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study. Int J Hematol. 2015; 102:420–425.

11. Kang HJ, Lee SS, Byun BH, et al. Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2013; 71:945–953.

12. Kim SJ, Kang HJ, Kim JS, et al. A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas. Invest New Drugs. 2013; 31:1514–1521.

13. Kim SJ, Yang DH, Kim JS, et al. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol. 2014; 93:1895–1901.

14. Jung SH, Lee JJ, Kim WS, et al. Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). Eur J Haematol. 2015; 94:504–510.

15. Park BB, Kim WS, Suh C, et al. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. Ann Hematol. 2015; 94:1845–1851.